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ABSTRACT  16 
The goal of the current work was to perform an integrated evaluation of monepantel (MNP) 17 
pharmacokinetics (PK) and pharmacodynamics, measured as anthelmintic efficacy, after its 18 
oral administration to calves naturally infected with GI nematodes resistant to ivermectin 19 
(IVM) and ricobendazole (RBZ) on three commercial farms. On each farm, forty-five calves 20 
were randomly allocated into three groups (n= 15): MNP oral administration (2.5 mg/kg); IVM 21 
subcutaneous (SC) administration (0.2 mg/kg); and RBZ SC administration (3.75 mg/kg). Eight 22 
animals from the MNP treated group (Farm 1) were selected to perform the PK study. Drug 23 
concentrations were measured by HPLC. The efficacy was determined by the faecal egg 24 
count reduction test (FECRT). MNP and MNP-sulphone (MNPSO2) were the main analytes 25 
recovered in plasma. MNPSO2 systemic exposure was markedly higher compared to that 26 
obtained for MNP. Higher Cmax and AUC values were obtained for the active MNPSO2 27 
metabolite (96.8 ± 29.7ng/mL and 9220 ± 1720ng.h/mL) compared to MNP (21.5 ± 28 
4.62ng/mL and 1709 ± 651ng.h/mL). The MNPSO2 AUC value was 6-fold higher compared to 29 
the parent drug. Efficacies of 99% (Farm 1), 96% (Farm 2) and 98% (Farm 3) demonstrated 30 
the high activity of MNP (P< 0.05) against GI nematodes resistant to IVM (reductions 31 
between 27 and 68%) and RBZ (overall efficacy of 75% on Farm 3). While IVM failed to 32 
control Haemonchus spp. and Cooperia spp., and RBZ failed to control Coooperia spp. and 33 
Ostertagia spp., MNP achieved 100% efficacy against Haemonchus spp., Cooperia spp. and 34 
Ostertagia spp. However, a low efficacy of MNP against Oesophagostomum spp. (efficacies 35 
ranging from 22 to 74%) was observed. In conclusion, oral treatment with MNP should be 36 










The work described here reports for the first time an integrated assessment of MNP 38 
pharmaco-therapeutic features and highlights the need to be considered as a highly valuable 39 
tool to manage nematode resistant to other chemical families.   40 
 41 













Considering the increasing prevalence and worldwide dissemination of gastrointestinal (GI) 46 
nematodes resistant to most of the available anthelmintic families, drug resistance is 47 
considered one of the main sanitary problems in extensive cattle production systems today 48 
(Kaplan, 2020). During the last decades, chemical control has been mainly based on the use 49 
of only three anthelmintic chemical families:  macrocyclic lactones (ML), benzimidazoles 50 
(BZD) and imidazothiazoles. Furthermore, since GI parasitism has a high impact on animal 51 
production, these anthelmintic drugs have been intensively used at short intervals in 52 
different cattle production grazing systems worldwide. This heavy reliance on anthelmintics 53 
to control parasitism and the limited implementation of refugia-based sustainable control 54 
programmes have led to the development of resistance to all the available chemical groups. 55 
Unfortunately, resistance is becoming a worldwide serious problem, particularly in countries 56 
such as New Zealand (Waghorn et al., 2006), Brazil (Ramos et al., 2016), Australia (Rendell, 57 
2010), Uruguay (Mederos et al., 2019), United States (Kaplan, 2020) and Argentina (Cristel et 58 
al., 2017) among many others. Despite the complex current situation regarding the 59 
widespread development of anthelmintic resistance, dependence on chemically-based 60 
control continues to be high since it is still the most practical option for parasite control on 61 
commercial beef cattle farms. 62 
 63 
The increasing levels of resistance to all traditional drug classes and the still high 64 
dependence on anthelmintics for controlling parasitic nematodes, have encouraged the 65 










pharmaceutical market. The compound monepantel (MNP) is a compound of a new family of 67 
anthelmintics, the amino-acetonitrile derivatives, developed to treat ruminants infected 68 
with GI nematodes (Kaminsky et al., 2008). Its mode of action is different from the other 69 
available anthelmintic families since it acts as a positive allosteric modulator of the 70 
nematode specific acetylcholine receptor MPTL-1 (Rufener et al., 2009, 2010). MNP binding 71 
to this receptor results in a constant uncontrolled flux of ions and finally in a depolarization 72 
of muscle cells leading to nematode paralysis (Epe and Kaminsky, 2013). The cellular target 73 
of MNP, the MPTL-1 receptor, is so far only present in nematodes, which might explain the 74 
excellent tolerability of MNP in mammals and its high efficacy against multidrug-resistant 75 
parasites to other anthelmintic classes in sheep and cattle (Baker et al., 2012; King et al., 76 
2015). The first formulation of MNP, launched in 2009, was licensed for exclusive use in 77 
sheep, and some years later was also introduced in a limited number of countries as an oral 78 
formulation for use in cattle (King et al., 2015). The disposition kinetics and distribution to 79 
target tissues of MNP have been previously described in sheep (Lifschitz et al., 2014), and 80 
some data on plasma profiles in dairy cows have been also reported (Ballent et al., 2017). 81 
However, until now there have been no published reports regarding the relationship between 82 
MNP pharmacokinetics and its efficacy against resistant GI nematodes in beef cattle.  83 
 84 
The goal of the work described here was to perform an integrated evaluation of MNP 85 
pharmacokinetics (PK) and pharmacodynamics (PD), assessed as anthelmintic efficacy, after 86 
its oral administration to calves naturally infected with GI nematodes resistant to ivermectin 87 











2. MATERIAL AND METHODS 90 
2.1. Field Trial 91 
This study was conducted on three cattle commercial farms located in the Humid Pampean 92 
Region, Argentina. All farms (Farms 1, 2 and 3) had a grazing system of meat production 93 
representative of Argentina bovine production. The resistance status of the nematode 94 
population characteristic of each farm was previously determined by the faecal egg count 95 
reduction test (FECRT) (Canton et al., 2019). In this way, the study included two farms with a 96 
predominance of IVM and RBZ-resistant nematode population (Farms 1 and 3) and one farm 97 
with only an IVM-resistant nematode population (Farm 2). 98 
 99 
2.2. Animals 100 
All the farms involved in the trial raise calves acquired from other producers. The herd on 101 
each farm from which the animals were selected were treated with levamisole prior to the 102 
study to remove their worm infections. It is important to point out that resistance to 103 
levamisole has not been reported in this region of Argentina (Cristel et al., 2017). They had 104 
then grazed on the study farms for at least two months prior to the study, which ensured 105 
that their parasite burden was native from each Farm. All the animals had free access to 106 
water. 107 
 108 
On day -1, 60 (Farms 1 and 3) or 80 (Farm 2) male Aberdeen Angus calves, aged 9–11 109 










or resistant to IVM (Farm 2), were checked for worm egg per gram (EPG) counts, ear-tagged, 111 
and the individual body weights were recorded. The animals for inclusion in the trial were 112 
then selected based on the EPG counts. Forty-five (45) animals on each farm, with at least 113 
100 EPG on day -1, were selected for inclusion in the study. Experimental animals had an 114 
average of 508 EPG counts ranging from 100 to 2440 on Farm 1, 274 EPG counts ranging from 115 
100 to 660 on Farm 2, and 450 EPG counts ranging from 140 to 1440 on Farm 3. 116 
 117 
Animal procedures and management protocols were approved by the Ethics Committee (act 118 
11/2020) of the Facultad de Cs. Veterinarias, Universidad Nacional del Centro de la Provincia 119 
de Buenos Aires (UNCPBA), Tandil, Argentina. 120 
 121 
2.3. Treatments 122 
On each farm (1, 2 and 3), all parasitized animals (n= 45) were ranked according to EPG counts, 123 
and then randomly assigned into three groups of 15 animals each: MNP:  animals were treated 124 
with MNP (Zolvix®, 2.5% solution, Elanco, Argentina) by the oral route at a dose of 2.5 mg/kg; 125 
IVM: animals were treated with IVM (Ivomec®, 1% solution, Boehringer Ingelheim, Argentina) 126 
by the subcutaneous (SC) route at 0.2 mg/kg and RBZ: animals were treated with RBZ 127 
(Bayverm PI®, 15% solution, Bayer, Argentina) by the SC route at 3.75 mg/kg. The mean EPG 128 
were similar (P> 0.05) across all groups on each farm at the beginning of the trial. 129 
 130 










The PK trial was carried out on Farm 1. Eight randomly selected animals from the MNP 132 
treated group were used in the PK trial. Blood samples (10 mL) were taken from the jugular 133 
vein in heparinised Vacutainer

 tubes (Becton Dickinson, NJ, USA) before treatment and at 134 
2,4, 6, 8 and 10 h and 1, 2, 3, 5, 7 and 9 days post-treatment.  Plasma was separated by 135 
centrifugation at 3000 g for 15 min, placed into plastic tubes and frozen at -20°C until 136 
analysis by High Performance Liquid Chromatography (HPLC). 137 
 138 
2.5. Anthelmintic efficacy trial: faecal egg count reduction test and coprocultures 139 
Faecal samples were individually collected directly from the rectum of each calf during pre-140 
treatment (day -1) and again on day15 post-treatment. A modified McMaster technique with a 141 
sensitivity of 10 EPG (Roberts and O’sullivan, 1950) was used to analyse the faecal samples and 142 
estimate EPG counts.  Additionally, 10 g of faeces (obtained from an individual animal and/or 143 
from a pool of each experimental group) was used to prepare coprocultures on each sampling 144 
day. The nematode genera and species were identified through the third-stage larvae 145 
recovered from these coprocultures (MAFF, 1986). Third stage larvae (L3) were collected by 146 
the Baermann technique and approximately 100 L3 were differentiated from each sample. 147 
Thus, the relative participation of each genus per experimental group was determined. 148 
 149 
The anthelmintic efficacy of the different treatments was assessed by the faecal egg count 150 
reduction test (FECRT), calculated according to the following formula (McKenna, 1990): 151 










where T2 is the arithmetic mean EPG count in each treated group at 15 days post-treatment, 153 
and T1 is the arithmetic mean EPG count in each treated group on day -1. The 95% confidence 154 
intervals were calculated as reported by Coles et al. (1992). Besides, efficacy against different 155 
genera was calculated by dividing the mean faecal egg count of each treatment group at day -156 
1 and 15 post-treatment, by the proportion of L3 of each genus in the associated coproculture 157 
(McKenna, 1990). 158 
 159 
2.6. Analytical procedures 160 
MNP and its metabolite, MNP-sulphone (MNPSO2), concentrations were determined in 161 
plasma by HPLC with UV detection. Briefly, MNP/MNPSO2 were extracted from plasma (0.5 162 
mL) by the addition of 1 mL of acetonitrile. The preparation was mixed with a high-speed 163 
shaker (Multi Tube Vortexer, VWR Scientific Products, West Chester, PA) for 15 minutes at 164 
room temperature to allow phase separation. The solvent-sample mixture was centrifuged 165 
at 2000 g for 10 min at 4 °C and the supernatant was manually transferred into a clean tube. 166 
This volume was evaporated to dryness under a gentle stream of dry nitrogen at 56 °C in a 167 
water bath. Finally, the dried residue was reconstituted with 250 µL of mobile phase 168 
(acetonitrile:methanol:water 60:8:32, v/v/v) and 200 µL of this solution was injected directly 169 
into the chromatography system. 170 
 171 
MNP plasma concentration was determined by HPLC (Shimadzu 10 A-HPLC System, Kyoto, 172 
Japan) with a UV detector set at 230 nm following a method previously developed (Ballent et 173 










Bohus, Sweden, 5 μm, 4.6 × 250 mm) was used for separation. Elution of MNP and MNPSO2 175 
from the stationary phase was carried out at a flow rate of 0.8 mL/min (MNP) using 176 
acetonitrile/methanol/water (60:8:32, v/v/v). Under the described chromatographic 177 
conditions, the retention times (min) were established at 9.3 (MNPSO2) and 12.5 (MNP). 178 
There was no interference of endogenous compounds in any of the chromatographic 179 
determinations. A calibration curve in the range between 4-400 ng⁄mL was prepared for 180 
both molecules.  The plasma calibration curve had a correlation coefficient ≥ 0.998. Mean 181 
absolute recovery percentages for concentrations ranging between 4 and 400 ng⁄mL (n= 6) 182 
were 74.9% (MNP) and 74.1% (MNPSO2) with coefficients of variation (CV) of 14.1% and 183 
15.7, respectively. Accuracy (expressed as the relative error) and precision (expressed as the 184 
coefficient of variation) were 10% and 5.2%, respectively. The limit of quantification (LOQ) 185 
was established at 4 ng⁄mL for MNP and MNPSO2, which is the lowest concentration 186 
measured with a recovery higher than 70% and a CV < 20%. In all cases, concentration values 187 
below the LOQ were not considered for the kinetic analysis of experimental data. 188 
 189 
2.7. Pharmacokinetic analysis of the data 190 
The concentration vs. time curves for MNP and MNPSO2 in plasma for each animal after the 191 
different treatments was fitted with the PK Solution 2.0 software (Summit Research Service, 192 
CO, USA). The peak concentration (Cmax) and time to peak concentration (Tmax) were 193 
recorded directly from the measured concentration data. The elimination half-life (T½el) and 194 
absorption half-life (T½abs) were calculated as ln2/λel and ln 2/kabs, respectively, where λel is 195 










The rates were calculated by performing regression analysis using data points belonging to 197 
the terminal or absorption phase concentration-time plot. The area under the plasma 198 
concentration-time curve from zero up to the quantificationlimit (AUC0-LOQ) was calculated 199 
using the trapezoidal rule (Gibaldi and Perrier, 1982) and further extrapolated to infinity 200 
(AUC0-∞) by dividing the last experimental concentration by the terminal elimination rate 201 
constant (λel). Statistical moment theory was applied to calculate the mean residence time 202 
(MRT) according to Perrier and Mayersohn (1982). PK analysis of the experimental data was 203 
performed using a non-compartmental model method. 204 
 205 
2.8. Statistical analysis of the data 206 
The PK parameters and concentration data are reported as arithmetic mean ± Standard 207 
Deviation (SD). PK parameters for MNP and MNPSO2 were statistically compared using 208 
Student t-test. Faecal egg counts (reported as arithmetic mean ± SD) were compared by non-209 
parametric Kruskal–Wallis test. A value of P<0.05 was considered statistically significant. The 210 
statistical analysis was performed using the Instat 3.0 software (Graph Pad Software, CA, USA). 211 
 212 
3. RESULTS 213 
MNP and MNPSO2 were the main analytes recovered in plasma after oral administration of 214 
MNP to cattle. The mean (± SD) plasma concentrations profiles of MNP and its MNPSO2 215 
metabolite are shown in Fig. 1. MNPSO2 systemic exposure was markedly higher compared 216 
to that obtained for MNP. It accounted for >80 % of the total amount of the analytes 217 










120 h (5 days) post-administration, the persistence of the sulphone metabolite was longer in 219 
the bloodstream, being recovered up to 216 h (9 days). These differences were reflected in 220 
the values estimated for the main PK parameters. Table 1 summarizes the plasma PK 221 
parameters for MNP and MNPSO2 obtained after the oral administration of MNP to cattle. 222 
Higher Cmax and greater AUC values were obtained in plasma for MNPSO2 compared to 223 
MNP. In fact, the AUC value for MNPSO2 were 6-fold higher compared to those reported for 224 
the parent drug (MNPSO2/MNP AUC ratio= 5.99 ± 2.08). 225 
 226 
Table 2 shows the overall faecal egg counts (arithmetic mean) and reduction percentages of 227 
faecal egg counts (FECR) (undifferentiated) with its 95% lower and upper confidence 228 
intervals obtained for all experimental groups on Farms 1, 2 and 3. The results of the FECRT 229 
with 99%, 96% and 98% of reduction for MNP on Farms 1, 2, and 3, respectively, 230 
demonstrated the high efficacy of this amino-acetonitrile derivative against GI nematodes 231 
resistant to IVM and RBZ in cattle. In fact, the low efficacies obtained for IVM (43%, 68% and 232 
27% of reduction) confirm the presence of resistant parasites to this anthelmintic. On the 233 
other hand, the overall efficacy for RBZ on Farm 2 was98%, demonstrating that this farm was 234 
the only one included in the study with a predominance of a RBZ-susceptible nematode 235 
population. Although the total efficacy for RBZ on Farm 1 was 94%, the 95% lower 236 
confidence interval for this anthelmintic was less than 90%, indicating an initial level of 237 
resistance. Finally, a higher level of resistance for RBZ was reported on Farm 3, where an 238 
overall reduction of 75% confirms the presence of resistant GI nematodes. In this context, 239 










counts post-IVMand MNP treatments, on Farm 3, the EPG counts after MNP were 241 
significantly (P< 0.05) lower than the egg counts after both IVM and RBZ.  242 
 243 
The anthelmintic efficacies against Cooperia spp., Haemonchus spp., Ostertagia spp. and 244 
Oesophagostomum spp. for the different treatments on Farms 1, 2 and 3, are shown in Table 245 
3. On Farms 1 and 3 IVM failed to control Haemonchus spp. and Cooperia spp., showing 246 
efficacies ranging from 0% to 80%. In the case of Farm 2, only IVM-resistant Cooperia spp. 247 
was present, being the others GI nematode genera susceptible to RBZ. The BZD treatment 248 
failed to control Cooperia spp. and Ostertagia spp. on Farms 1 and 3 (FECR below 90% for 249 
both nematode genera). In contrast, MNP was the only treatment that achieved 100% 250 
efficacy against Cooperia spp., Haemonchus spp. and Ostertagia spp., including against 251 
resistant parasites (99% against Ostertagia spp. on Farm 3). However, MNP failed to control 252 
Oesophagostomum spp., showing low efficacies of 74%, 22% and 64% against this genus on 253 
Farms 1, 2, and 3, respectively.  254 
Finally, no adverse events were observed in any of the cattle treated with MNP. 255 
 256 
4. DISCUSSION 257 
Since GI parasitism negatively affects weight gain in grazing animals (Charlier et al., 2014a), 258 
parasite control is necessary to ensure adequate production levels on beef cattle farms. 259 
Alternative nematode control strategies, such as grazing management, host genetic 260 
resistance and helminth vaccines, are now being developed for further reduce reliance on 261 










anthelmintics continues to be high, since it is still being the most practical tool for parasite 263 
control on large scale commercial beef cattle farms. Due to the enormous difficulties 264 
involved in the development of novel anthelmintic molecules, such as the lastly introduced 265 
amino-acetonitrile derivative MNP, it is essential to understand its pharmacological 266 
behaviour to optimize its use in cattle under natural field conditions. The work described 267 
here reports for the first time an integrated assessment of MNP pharmacokinetics and 268 
pharmacodynamics (measured as anthelmintic efficacy), in cattle naturally infected with GI 269 
nematodes resistant to IVM and RBZ on a field trial performed on three different commercial 270 
farms. 271 
 272 
The MNP plasma disposition kinetics has not been described in beef cattle. However, in line 273 
with previous PK studies in sheep (Karadzovska et al., 2009; Lifschitz et al., 2014) and dairy 274 
cows (Ballent et al., 2017), a rapid decline in the plasma profiles of the parent drug and the 275 
recovery of the MNPSO2 metabolite as the main analyte detected in the bloodstream, were 276 
observed in beef calves in the current trial.  The metabolic conversion of MNP into MNPSO2 277 
also involves the production of an intermediate sulphoxide derivative (Karadzovska et al., 278 
2009), which is rapidly and almost completely converted into MNPSO2, being undetectable 279 
in plasma of MNP treated animals. In fact, the Cmax of the sulphone metabolite was four 280 
times higher than the corresponding parent concentration (21.5 vs 96.8 ng/mL for MNP and 281 
MNPSO2, respectively). Moreover, when MNP reached the Cmax (at 8 h post-oral 282 
treatment), the MNPSO2 metabolite was already about twice as high. Since MNPSO2 is an 283 










exposure greatly contribute to the overall MNP nematodicidal efficacy. In fact, the ratio of 285 
the total plasma AUC of MNPSO2 over the total AUC of MNP in both species, exhibited higher 286 
systemic exposure for MNPSO2 compared to the parent drug after the oral administration of 287 
MNP. However, interspecies differences in MNPSO2 systemic availability were observed 288 
between cattle and sheep. While Lifschitz et al. (2014) reported a MNPSO2/MNP AUC ratio 289 
of about 12 in sheep, a 50% lower value is described for that ratio after oral administration 290 
of MNP in cattle (Table 1). This finding may be explained by the different patterns of MNP 291 
liver metabolism (S-oxidation) between sheep and cattle. The rate of MNP conversion into 292 
MNPSO2 was five-fold higher in sheep compared to cattle (Ballent et al., 2016).  While in 293 
sheep, the formation of the sulphone metabolite is based on the enzymatic activity of both 294 
flavin-monooxygenase (FMO) and cytochrome P- 450 (CYP), in cattle MNP is converted into 295 
MNPSO2 only in a CYP- mediated metabolic reaction (Ballent et al., 2016). These interspecies 296 
differences do not necessarily imply lower exposure of worms to the active drug. Moreover, 297 
considering MNP anthelmintic activity may be mainly based on a considerable 298 
drug/metabolite accumulation in the GI tissues and fluid contents during the first 2 to 3 days 299 
post-treatment, the different patterns of MNP liver metabolism between sheep and cattle 300 
should not affect its efficacy against GI nematodes (Lifschitz et al. 2014). 301 
 302 
The results of the current PK assessment in cattle and those reported in sheep by Lifschitz et 303 
al. (2014) on the characterization of MNP accumulation in target tissues, give strong 304 
pharmacological support to the anthelmintic efficacy findings. The increasing worldwide 305 










ML and BZD, therapeutic failures associated with anthelmintic resistance has enormous 307 
economic importance of global significance, particularly in countries where weather and 308 
production conditions contribute to a high incidence of parasitism. For instance, resistance 309 
to IVM was diagnosed in 93% of the farms tested in Argentina, while resistance to RBZ was 310 
diagnosed in 28% of the farms included in a nation-wide survey (Cristel et al.,2017). The 311 
main resistant genera were Cooperia spp. and Haemonchus spp. to IVM, and Ostertagia spp. 312 
and Cooperia spp.to RBZ (Cristel et al., 2017). Therefore, the efficacy of MNP was evaluated 313 
in scenarios where the nematode population was representative of the real situation on 314 
most commercial cattle farms. In this context, the efficacy results showed 99%, 96% and 98% 315 
of reduction for MNP on Farms 1, 2 and 3, respectively. These results demonstrated the high 316 
efficacy of MNP against resistant GI nematodes in cattle. Only limited information is 317 
available on MNP efficacy against GI nematodes in cattle (King et al. 2015). In that particular 318 
trial, MNP was administered in a combined formulation with abamectin. However, the 319 
reported efficacy results are consistent with those observed in our current trial with 320 
efficacies measured by FECR ranging from 98.3 to 99.9%.  Similarly, the efficacy results 321 
observed in the present work are consistent with several studies in sheep (Bustamante et al., 322 
2009; Hosking et al., 2009; Kaminsky et al., 2009; Sager et al., 2009). Bustamante et al. 323 
(2009) also evaluated MNP efficacy against IVM resistant nematode parasites. The low IVM 324 
efficacies obtained in the current work (43%, 68% and 27% of reduction on Farms 1, 2 and 325 
3), confirm the presence of resistant nematode populations to this ML anthelmintic. 326 
Additionally, MNP was the only treatment that achieved >95% both in the overall efficacy 327 











It should be considered that GI parasitism in cattle always involves different parasite genera. 330 
In this sense, while on Farms 1 and 3 IVM failed to control Cooperia spp. and Haemonchus 331 
spp., on Farm 2 Cooperia spp. was the only genus resistant to IVM. Cooperia spp. is 332 
commonly present in the cases of IVM resistance in cattle. In fact, resistant Cooperia spp.  333 
was recovered in 100% of the farms where resistance to IVM were present in a survey carried 334 
out in Argentina in 2017 (Cristel et al. 2017). Cooperia spp. is one of the genera in which 335 
resistance to IVM is more frequent not only because it is a “dose-limiting” parasite for IVM 336 
(Benz et al., 1989), but also because routine IVM treatments are administered in the absence 337 
of any significant larval population in refugia (Sauermann and Leathwick 2018). However, 338 
similarly to our findings, some studies have also reported both Cooperia spp. and 339 
Haemonchus spp. resistant to IVM (Anziani et al., 2004; Ramos et al., 2016; Canton et al., 340 
2018). Although RBZ achieved higher overall efficacies than IVM, the BZD treatment did not 341 
show effective control against all the GI nematodes present on Farms 1 and 3. Indeed, on 342 
these farms, RBZ failed to control Cooperia spp. and Ostertagia spp. (FECR below 90% for 343 
both nematode genera). In contrast, MNP was the only treatment that achieved 100% 344 
efficacy against Cooperia spp., Haemonchus spp. and Ostertagia spp. Similar results were 345 
found in different studies in sheep against resistant GI nematodes. Hosking et al. (2008) and 346 
Sager et al. (2009) demonstrated high (>95%) efficacy of MNP administered orally to sheep 347 
against GI nematodes resistant to either BZ or levamisole. Furthermore, Steffan et al. (2011) 348 









resistant to BZ, levamisole and ML. Although those studies were performed in sheep, their 350 
results and resistance scenarios were comparable with the current trial of MNP in cattle.  351 
 352 
Efficacy of MNP against Oesophagostomum spp. is a particularly relevant issue due to 353 
efficacy results failed to meet an adequate reduction. The findings of the present study in 354 
cattle demonstrated that MNP failed only to control Oesophagostomum spp., with efficacies 355 
ranging from 22% to 74%. Similarly, it has been reported in sheep that Oesophagostomum 356 
was only reduced by 88% (Sager et al., 2009) and 61.9% (Bustamante et al., 2009). 357 
Furthermore, Hosking et al. (2009) also found efficacies below 90% against this nematode in 358 
sheep. In fact, the dose of 2.5 mg/kg was established as a suitable minimum dose rate 359 
(Kaminsky et al., 2009), because lower doses failed to control Oesophagostomum spp., 360 
which was established as the dose-limiting nematode for MNP (Hosking et al., 2010). 361 
Although a reduced sensitivity of this genus to MNP may explain its low efficacy, Lifschitz et 362 
al. (2014) suggested that a PK-related issue should contribute to this limited therapeutic 363 
response in sheep. The lower concentration of MNP achieved in the large intestine mucosa 364 
(225 ng/g) compared to that measured in the small intestine mucosa (562 ng/g in the ileum 365 
and 762 ng/g in the duodenum) may explain the efficacy levels obtained against 366 
Oesophagostomum spp. (Lifschitz et al., 2014), situation that could also occur in cattle. The 367 
PK/PD of MNP against GI nematodes may suggest that the high concentrations of MNP 368 
parental drug achieved in the GI contents and mucosa during 48-72 h after its oral 369 











The activity of MNP against multidrug-resistant parasites, which is based on its novel mode 372 
of action, is a highly favorable element. However, resistance to MNP has occurred on the 373 
field within less than 2 years of the product first being used in sheep and goats in New 374 
Zealand. In this first report of resistance in goats excessively treated with the amino-375 
acetonitrile derivative, MNP was ineffective against at least two GI nematode species, 376 
Teladorsagia circumcincta and Trichostrongylus colubriformis (Scott et al., 2013). Moreover, 377 
Mederos et al. (2014) found Haemonchus contortus resistant to MNP on sheep farms in 378 
Uruguay. Lack of efficacy of MNP was also reported on sheep farms in the Netherlands (van 379 
den Brom et al., 2015), Brazil (Cintra et al., 2016), Australia (Sales and Love, 2016), Argentina 380 
(Illanes et al., 2018) and the United Kingdom (Hamer et al., 2018; Bartley et al., 2019). 381 
Considering that resistance to MNP has already been reported in sheep in different 382 
countries, it is essential to understand the mechanisms of resistance to this compound. In 383 
this way, the presence of multiple separate mutations in theMPTL-1gene in field-derived H. 384 
contortus and T. circumcincta isolates may at least partly explain MNP resistance (Bagnall et 385 
al., 2017; Turnbull et al., 2019). The reports of resistance highlight the need to learn from 386 
the use of this anthelmintic on sheep farms. It is essential to maintain the awareness on the 387 
possibility of development of resistance to MNP in cattle nematode parasites, which includes 388 
the need to follow appropriate guidelines of parasite control (Bartley et al., 2019). 389 
 390 
Overall, there is no published reports on the simultaneous assessment of the relationship 391 
between the PK performance and the anthelmintic therapeutic response to MNP in cattle. 392 










administration route for MNP in beef cattle. This is particularly relevant when the described 394 
high systemic exposure of the anthelmintically active MNP and MNPSO2 exposure is 395 
considered. MNP achieved effective control of GI nematodes with multiple anthelmintic 396 
resistance to ML and BZD. The widespread appearance of resistant parasites highlights the 397 
need for novel anthelmintics acting at novel target sites to be used in cattle, such as MNP. 398 
However, it is now crucial to accomplish adequate management of this novel compound to 399 
prolong its lifespan and optimize parasite control based on diagnosis and treatment 400 
strategies implemented on an individual cattle farm basis. The findings described here 401 
contribute to the knowledge on MNP pharmacology and efficacy against resistant GI 402 
nematodes in beef cattle. 403 
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Figure Legends 556 
Figure 1 557 
Plasma concentration profiles of monepantel (MNP) and monepantel sulphone (MNPSO2) 558 
obtained after the oral administration of monepantel (2.5 mg/kg) to parasitized calves (n=8). 559 
The insert shows the chemical structures of MNP and an its anthelmintically active 560 









Plasma pharmacokinetic parameters (mean ± SD) for monepantel (MNP) and monepantel 







Tmax (h) 8.00 ± 1.51
a
 41.3 ± 17.9
b
 
Cmax (ng/mL) 21.5 ± 4.62
a
 96.8 ± 29.7
b
 
AUC0-LOQ (ng.h/mL) 1709 ± 651
a
 9220 ± 1720
b
 
AUC0-∞ (ng.h/mL) 2174 ± 783
a
 10242 ± 1405
b
 
MRT (h) 112 ± 40.8
a
 99.3 ± 21.0
a
 
T½el (h) 81.0 ± 31.0
a
 57.6 ± 13.9
a
 
T½abs (h) 1.74 ± 0.66
a
 9.79 ± 4.06
b
 
Ratio of the AUC 
MNPSO2/MNP 
- 5.99 ± 2.08 
 
Tmax: time to peak plasma concentration; Cmax: peak plasma concentration; AUC0-LOQ: area 
under the plasma concentration vs. time curve from 0 to the quantification limit; AUC0-∞: 
area under the concentration-time curve extrapolated to infinity; MRT: mean residence 
time; T½el: elimination half-life; T½abs: absorption half-life (the value express the metabolite 
formation half-life for MNPSO2). 










Nematode egg per gram counts (EPG, arithmetic mean, range) and reduction percentages of faecal egg counts (FECR) 
(undifferentiated) with its 95% lower and upper confidence intervals, after the oral administration of monepantel (MNP, 2.5 mg/kg), 




FECR estimated according to McKenna, (1990). CI: lower and upper confidence intervals.  
EPG counts on each column with different superscript letters are statistically different (P<0.05). 
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Reduction percentages of faecal egg counts (FECR) for Cooperia, Haemonchus, Ostertagia 
and Oesophagostomum spp. after the oral administration of monepantel (MNP, 2.5 
mg/kg), and the subcutaneous administration of ivermectin (IVM, 0.2 mg/kg) and 
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100% 100% 100% 
80% 56% 43% 
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• MNP and its anthelmintically active metabolite MNPSO2 were the main analytes 
recovered in plasma 
• The MNPSO2 AUC value was 6-fold higher compared to the parent drug 
• MNP obtained overall efficacies of 96-99% against IVM and BZD resistant nematode 
parasites in cattle 
• MNP failed to control Oesophagostomum spp. 
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